Liz Shepherd is a co-founder of Novome Biotechnologies, a pre-clinical biotech company developing engineered gut bacteria as therapeutics. Liz worked on Novome's foundational platform technology during her PhD in Justin Sonnenburg's lab at Stanford University, where she developed a strategy for reliable engraftment of engineered bacteria into the gut microbiome. She first became interested in engineering biology during her undergraduate work in David Baker's lab at the University of Washington, where she worked on an engineered enzyme to break down the gluten protein. Current efforts at Novome are focused on bringing the company's lead drug candidate into phase I clinical trials, and continuing to expand the platform into new therapeutic areas.
